The Show-Me State Progress in Maternal Mortality



Outline

- What makes the Missouri PAMR and PQC so unique?
 - WHO (people and participants, PAMR and PQC partnership)
 - WHERE (MHA, state-wide participation)
 - WHAT and WHY (data to action)
 - HOW (AIM hypertension implementation and Missouri Cuff Kit Project)



What makes The Show-Me PAMR so unique....WHO

Respectful care for PATIENTS starts with respect for your TEAM MEMBERS





What makes The Show-Me PAMR so unique.... WHO

Respect for all members

Varied backgrounds and expertise

Collaborative and inclusive nature

Deep desire by all to make a difference

Eagerness to reach out to and collaborate with other MMRCs

What makes the Show-Me PAMR so unique....HOW

- Learn from other MMRCs
 - Utilization of the Texas discrimination toolkit
 - Frequently used recommendations
- No subcommittees or separate groups
- Adjudicate ALL deaths through 365 days
 - Lessons learned from both pregnancyrelated and pregnancy-associated deaths



YOU HAVE THE CAPACITY TO LEARN FROM YOUR MISTAKES.

You will learn a lot today.

What makes The Show-Me PAMR so unique....WHO



Pregnancy-Associated Mortality Review



What makes The Show-Me PAMR collaboration so unique....WHO

What makes the Show-Me PAMR so unique....HOW



Why are we seeing rising rates of SMM and MM??



Loop MS et al. Heat Maps of Hypertension, Diabetes Mellitus, and Smoking in the Continental United States. Circ Card Outcomes. 2017; 10 (1).

Taking Our Data to Action: WHAT we do

Figure 16: Pregnancy-Related Mortality Ratio per 100,000 Live Births by Race



Taking Our Data to Action: WHAT we do

Timing of Leading Underlying Causes of Pregnancy-Related Deaths, 2017-2019



Taking Our Data to Action: WHAT we do

Figure 22: Timing of Leading Underlying Causes of Pregnancy-Related Deaths, 2017-2019 Mental Health 35% 65% Conditions (17) Cardiovascular 44% 50% 5% Disease (16) 63% Injury (8) 38% Hemorrhage (6) 17% 83% 33% 33% 33% Embolism (3) Cerebrovascular 50% 50% Accident (2) Infection (1) 100% Gastrointestinal 100% Disorders (1) Amniotic Fluid 100% Embolism (1) 0% 25% 50% 75% 100% During Pregnancy 0-42 days postpartum ■ 43-365 days postpartum

Missouri Pregnancy Associated Mortality Review 2017-2019 Annual Report. Missouri Department of Health and Senior Services. (June 2022)

Taking Our Data to Action: HOW we do

140 120 100 80 100% 60 56% 40 66% 20 31% 29% 11% 0 **Mental Health CVD** Hemorrhage

Maternal Mortality and Preventability by Cause

Death Preventability

GOVERNOR PARSON ANNOUNCES NEW INVESTMENT, PARTNERSHIPS TO REDUCE MATERNAL MORTALITY IN MISSOURI

Missouri Maternal Quality Care Protocols DHSS is partnering with the Missouri Perinatal Quality Collaborative (MO PQC), led by the Missouri Hospital Association, to develop and implement standardized evidence-based protocols for maternal-fetal health care with toolkits including a collection of best practice tools and articles, care guidelines, a hospital-level implementation guide, and professional education materials.

Maternal Care Workforce DHSS and MO PQC are developing standardized maternal care provider trainings on trauma-informed, responsive, culturally congruent, and linguistically appropriate care, including screening, referral, and treatment of mental health conditions and substance use disorder during and after pregnancy as well as cardiovascular disorders, gestational diabetes, and other endocrinology disorders associated with pregnancy.

Optimize Postpartum Care DHSS and MO PQC are developing a standardized Postpartum Plan of Care to include an assessment for depression and anxiety, universal screening for substance use disorder, and (as appropriate) referrals to mental health professionals, social workers, community health workers, nurse-led home visiting programs, and substance use disorder treatment programs.

Maternal Health Access Project DHSS is working with the University of Missouri Health System to develop and implement a hub-and-spoke model Perinatal Health Access Conaborative, inclusive or perinatal mental health. The Collaborative will provide same-day specialized consultation, patient referral to community services, over-the-phone follow-up care coordination, and access to ongoing training and education for rural healthcare providers and other providers without this specialized expertise.

Improved Maternal Health Data

DHSS is establishing a maternal-child health dashboard to advance data quality and accessibility.

Cardiovascular-Related Deaths

- Contributing Factors
 - Access/financial
 - Assessment
 - Continuity of Care/Coordination of Care
- Recommendations
 - Expand access through Medicaid expansion
 - Education of providers (i.e. emergency room)
 - Create best practice alerts for pregnant or recently pregnant patients
 - Autopsy
 - Disagreed with underlying cause 20%



Focus on Cardiovascular-related Deaths

- Became AIM state in 2018 and established PQC
- Started with implementation of AIM HTN bundle (CVD-related)
 - PQC-led directive
- Voluntary participation of hospitals
 - 36 of the 62 hospitals participated
- Data tracking for 18 months
- Decided upon 2 metrics
 - Time to treatment
 - Follow-up
- Education campaign



WHY: CVD-related: Long-term Maternal Risks

- Cardiovascular disease
 - Preeclampsia predictive of future cardiovascular and cerebrovascular disease up to 9-fold
 - Risks are equal to that of *smoking or obesity*
 - Can occur as early as 3-5 years after delivery
 - Related to both severity and number of episodes
 - Higher with early onset, severe disease or associated growth restriction (*similar risk to someone with diabetes*)
 - <u>Permanent</u> arterial changes
 - Lifestyle interventions after preeclampsia can reduce risk by 4-13%, *but never back to baseline*

Long-term Maternal Risks



Preeclampsia and future cardiovascular health: A systematic review and meta-analysis *Wu P et al. Circulation Outcomes 2017*

Table 1. Sensitivity Analysis With Regard to Duration of Follow-Up

Outcomes		<1 y	1—10 y	>10 y		
Cardiovascular disease death	Adjusted		2.30 (1.65–3.20), n=1	2.21 (1.73–2.81), n=3		
Coronary heart disease	Adjusted	3.10 (1.56–6.15), n=1	3.78 (0.43–77.30), n=2	1.46 (0.95–2.25), n=3		
	Unadjusted			2.09 (1.64–2.66), n=3		
Coronary heart disease death	Adjusted			2.10 (1.25–3.51), n=4		
Heart failure	Adjusted	4.10 (2.90–5.80), n=1	8.42 (4.39–16.17), n=2	1.60 (0.73–3.50), n=1		
	Unadjusted		4.27 (2.09–8.71), n=1	2.73 (1.30–5.74), n=2		
Stroke	Adjusted	2.22 (1.73–2.85), n=2	3.56 (0.52–24.28), n=2	1.18 (0.95–1.46), n=2		
	Unadjusted			1.60 (1.47–1.74), n=1		

Values are represented as risk ratio (95% Cl). Cl indicates confidence interval.



Severe Hypertension in Pregnancy

 \wedge

Resources

- Safety Bundle Registration Form
- Implementation Support
 - Safety Bundle Program Resources
 - Maternal ED Flowchart

Webinars

- AIM Severe Hypertension in Pregnancy Bundle Implementation Recording
- Cardiac Disease in Pregnancy PowerPoint | Recording
- EleVATE Women Collaborative IHN PowerPoint | Recording
- Hypertensive Disorders in Pregnancy PowerPoint | Recording
- Severe Hypertension in Pregnancy Case Studies and Lessons Learned — PowerPoint | Recording
- Simulation in Obstetrics **PowerPoint** | **Recording**



Example Hospital in MO AIM HTN Bundle



Severe Blood Management Data

	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20	Jan-21	Feb-21	Mar- 21	Apr-21
SLH	37.0%	69.4%	75.0%	62.2%	63.9%	78.2%	80.5%	66.7%	90.0%	97.5%	100.0%	100.0%	100.0%	72.0%	100.0%	97.4%	100%	88.9%
SLE	25.0%	33.3%	26.3%	40.0%	30.8%	60.0%	66.7%	47.4%	83.3%	70.0%	100.0%	100.0%	64.7%	55.6%	92.3%	94.1%	100%	100%
SLN	100.0%	0.0%	0.0%	83.3%	62.5%	NP	25.0%	100.0%	100.0%	100.0%	100.0%	83.3%	NP	NP	100.0%	100.0%	100%	100%
SLS	NP	0.0%	100.0%	0.0%	NP	100.0%	NP	66.7%	100.0%	100.0%	NP	NP	100.0%	NP	66.7%	100.0%	NP	NP
НМС	75.0%	NP	NP	NP	0.0%	NP	NP	NP	NP	100.0%	0.0%	100.0%	NP	NP	NP	NP	NP	100%
SLHS	40.0%	56.7%	60.3%	59.0%	55.2%	77.8%	63.2%	67.2%	89.4%	92.6%	96.1%	98.4%	78.6%	67.6%	97.5%	96.8%	100%	95.2%

Example Hospital in **MO AIM** HTN Bundle



Follow up Appointment Data

	Nov-19	Dec-19	Jan-20	Feb-20	Mar-20	Apr-20	May-20	Jun-20	Jul-20	Aug-20	Sep-20	Oct-20	Nov-20	Dec-20	Jan 2021	Feb-21	Mar-21	
SLH	67.5%	83.7%	91.7%	94.7%	97.0%	96.0%	93.2%	97.1%	97.9%	100.0%	97.8%	91.9%	89.5%	93.3%	90.5%	97.4%	97.5%	100%
SLE	75.0%	71.4%	63.2%	73.7%	82.1%	90.0%	70.8%	92.6%	92.3%	80.0%	84.2%	100.0%	83.3%	87.5%	100.0%	100.0%	85%	100%
SLN	50.0%	100.0%	100.0%	50.0%	27.2%	100.0%	66.7%	40.0%	60.0%	37.5%	100.0%	50.0%	25.0%	100%	87.5%	87.5%	100%	100%
SLS	0.0%	50.0%	100.0%	100.0%	100.0%	40.0%	0.0%	100.0%	100.0%	100.0%	100.0%	33.3%	66.7%	50.0%	75.0%	66.7%	66.7%	NP
НМС	83.3%	50.0%	88.9%	100.0%	75.0%	100.0%	100.0%	100.0%	100.0%	66.7%	86.7%	100.0%	80.0%	75.0%	NP	100.0%	50%	100%
SLHS	69.2%	78.1%	84.3%	86.4%	82.6%	83.0%	81.0%	88.6%	94.4%	86.8%	92.8%	88.2%	82.4%	86.8%	93.5%	94.9%	90.4%	100%

Overall Results from AIM Implementation

- 29 organizations met minimum reporting criteria for HTN bundle
 - Median time to treatment for severe HTN improved by 25%
 - 91% of bundle elements were implemented
 - 90% of structure elements were implemented



MO AIM: Rate of Antihypertensive Med Given within 1 Hr. of Severe HTN Episode



Now what.....



GOVERNOR PARSON ANNOUNCES NEW INVESTMENT, PARTNERSHIPS TO REDUCE MATERNAL MORTALITY IN MISSOURI

Missouri Maternal Quality Care Protocols | DHSS is partnering with the Missouri Perinatal Quality Collaborative (MO PQC), led by the Missouri Hospital Association, to develop and implement standardized evidence-based protocols for maternal-fetal health care with toolkits including a collection of best practice tools and articles, care guidelines, a hospital-level implementation guide, and professional education materials.

Maternal Care Workforce | DHSS and MO PQC are developing standardized maternal care provider trainings on trauma-informed, responsive, culturally congruent, and linguistically appropriate care, including screening, referral, and treatment of mental health conditions and substance use disorder during and after pregnancy as well as cardiovascular disorders, gestational diabetes, and other endocrinology disorders associated with pregnancy.

Optimize Postpartum Care DHSS and MO PQC are developing a standardized Postpartum Plan of Care to include an assessment for depression and anxiety, universal screening for substance use disorder, and (as appropriate) referrals to mental health professionals, social workers, community health workers, nurse-led home visiting programs, and substance use disorder treatment programs.

Maternal Health Access Project | DHSS is working with the University of Missouri Health System to develop and implement a hub-and-spoke model Perinatal Health Access Collaborative, inclusive of perinatal mental health. The Collaborative will provide same-day specialized consultation, patient referral to community services, over-the-phone follow-up care coordination, and access to ongoing training and education for rural healthcare providers and other providers without this specialized expertise.

Improved Maternal Health Data | DHSS is establishing a maternal-child health dashboard to advance data quality and accessibility.

Figure 5: Hypertension During Pregnancy by Race Ratio per 10,000 2017-2019



White Black Hispanic Other

Focus on Postpartum Hypertension

Figure 10: Timing of Death by Relationship to Pregnancy, 2017-2019



Pregnancy-Associated, Not Related Pregnancy-Related Unable to Determine

HBPM Postpartum

	Teleh (n=2	Telehealth (n=214)		Selehealth c n=214) c		Stand elehealth outpa 1=214) care (dard atient (<i>n</i> =214)	P value	- RR (95% CI)	Adjusted <i>P</i> value	Adjusted RR (95% CI)
Healthcare utilization through 6 wk												
Hypertension-related hospital readmissions ^a , n (%)	1	(0.5)	8	(3.7)	.037	0.13 (0.02-0.99)	.045	0.12 (0.01-0.96)				
Hypertension-related emergency or triage room visits ^a , n (%)	11	(4.6)	13	(6.0)	.831	0.76 (0.38—1.85)	.808	0.81 (0.36-1.80)				
Number of blood pressure reviews within 10 days of delivery ^a , n (%)	202	(94.4)	129	(60.3)	<.001	1.56 (1.39—1.76)	<.001	1.59 (1.36–1.77)				
6 wk study endpoint												
Number of participants on antihypertensive treatment regimes ^a , n (%)	57	(26.6)	37	(17.3)	.027	1.54 (1.06-2.23)	.866	1.03 (0.74-1.44)				
Data are expressed as mean, median (interquartile range),	or <i>n</i> (%)											
<i>Cl</i> , confidence interval; <i>RR</i> , relative risk; <i>SD</i> , standard devi ^a Adjusted for the delivery mode, insurance status, antihyp	ation. pertensior	medication	use at th	ie time of hosp	ital discharge,	and the total number of po	stpartum admiss	ion days.				

Compliance with SMBP





"THE SOFTWARE HELPS ME TO BETTER MONITOR MY BLOOD PRESSURE" N = 82 80 74.4% 70 60 20 50 Ν 30 18.3% 20 6.1% Number of days of HBPM 🚯 1.2% l somewhat l agree I somewhat I strongly disagree disagree agree



Figure 3 Compliance according to the consecutive number of days of HBPM.

Figure 5 Women's opinions regarding the Hy-result system's usefulness.

Patient Satisfaction with SMBP

Table 3 Univariate logistic regression results

Domain	Question	Variable	Odds Ratio (OR)	Standard Error (SE)	95% Cl
Burden of care	To what extent do you prefer going to the hospital or clinic instead of using the mHealth technology at home?	No significant variables			
	How much would you recommend the mHealth technology to other women in your situation?	Gestational hypertension	12	17.4	0.71- 204
		Preeclampsia without severe features	36*	54.7	1.86- 701
		All other preeclampsia	24*	31	1.9– 294
		Starting medication after discharge	4.1*	2.9	1.0– 16.4
		Non-Hispanic White	7.6+	7.1	1.2– 47.4
Satisfaction	How enjoyable are the mHealth devices to use?	All other preeclampsia	12.7*	13	1.7– 94.2
		Chronic hypertension	8.8+	11	0.77- 101
	Overall how satisfied are you with the mHealth devices?	All other preeclampsia	19*	26	1.3– 283
		Moternal Divis	0.24	0.03	0.88- 0.99
		Infant discharging with mother	4.4+	3.48	0.90- 21
		Starting medication after discharge	3.1+	1.9	0.94- 10

Cost Effectiveness of SMBP

Table 3. Summary of reviewed studies.

		Study	Time	Conditions	Intervention vs control	Cost- effectiveness
		Ahmed et al ³⁰	Prenatal	HDP	Tight control vs less tight control of HDP	+
		Barton et al ³¹	Prenatal	HDP	Outpatient monitoring vs antepartum hospitalization	+
		Brooten et al ³²	Prenatal	HDP	Half of prenatal care in home by nurse specialists vs usual prenatal care	+
		Buysse et al ³³	Prenatal	HDP	Telemonitoring vs in-hospitalized monitoring	+
gure 1. Study fra	mewo	Drost et al ³⁴	Postpartum	History of HDP	Annual hypertension screening in primary care vs usual care	+
		Dunlop et al ³⁵	Prenatal	HDP	Day care management vs inpatient care	+
a where the		Harrison et al ³⁶	Prenatal	HDP	In-home care vs in-hospital antenatal care	-
Early Life P	rior HDP/	Kim et al ³⁷	Postpartum	History of GDM	screening strategy for preventing T2DM	+ (if used less frequent screening)
		Kolu et al ³⁸	Prenatal	Risk factors for GDM including history of GDM	gestational lifestyle intervention during pregnancy vs routine care	
		Lagerweij et al ³⁹	Postpartum	History of HDP	Early preventive cardiovascular disease risk screening followed by risk-based lifestyle interventions vs no screening	
	Prena	Lanssens et al ⁴⁰	Prenatal	HDP	Remote monitoring vs conventional care	+
	Ten	Mallampati et al ⁴¹	Prenatal	Risk factors for pre-eclampsia including history of HDP	Low-dose aspirin prophylaxis program vs routine care	+
		Marseille et al ⁴²	Prenatal + postpartum	Risk factors for GDM including history of GDM and found GDM	Screening followed by antenatal care (diet and exercise counseling, glucose control medications and monitoring) and postpartum care (metformin or lifestyle management) vs routine care	+
		Moss et al ⁴³	Prenatal	GDM	Treating mild GDM vs routine pregnancy care	+ (in high-income countries)
		Ohno et al ⁴⁴	Prenatal	GDM	Treating mild GDM vs routine pregnancy care	+
		Poncet et al ⁴⁵	Prenatal	Risk factors for GDM including history of GDM	Screening high-risk women with 50 g OGTT vs screening all pregnant women with 50 g or 75 g OGTT	+
		Simon et al ⁴⁶	Prenatal	HDP	Administration of magnesium sulfate vs placebo	+ (in low gross national income countries)
OM indicates gestation	al diabe	Todorova-Ananieva ⁴⁷	Postpartum	History of GDM	Prophylactic program (advice of dietary regimen, reduction of body weight and lifestyle alternation) for preventing T2DM	+
		van Baaren et al ⁴⁸	Postpartum	History of HDP	Preventive screening on cardiovascular risk factors followed by subsequent antihypertension medication vs no follow- up	+
		Vijgen et al ⁴⁹	Prenatal	HDP	Induction of labor vs expectant monitoring	+
		Werner et al ⁵⁰	Prenatal	Risk factors for pre-eclampsia including history of HDP	Low-dose aspirin prophylaxis program vs routine care	+
		Xydopoulos et al ⁵¹	Prenatal	HDP	Home blood pressure monitoring vs traditional monitoring	+

Note. "+" means cost-effective and "-" means not cost-effective.

GDM indicates gestational diabetes mellitus; HDP, hypertensive disorders of pregnancy; OGTT, oral glucose tolerance test; T2DM, type 2 diabetes mellitus.

The Cuff Kit Project

- Grant #1 from the Missouri Foundation for Health
 - Focus on equity, decreasing disparities and elevating the community voice
 - Must also partner with community organizations (not just hospitals)
 - Distributed ~3000 cuff kits to vulnerable, at-risk maternal populations
- Grant #2 from MO DHSS COVID-19 Health Equity Funding
 - Distributed ~4400 cuff kits to vulnerable, at-risk maternal populations
 - Research on efficacy underway
- Partnership with the Preeclampsia Foundation
- Distribution of blood pressure kits to postpartum birthing people with pre-eclampsia





The Cuff Kit[™] Project Resources

 $\boldsymbol{\wedge}$

Webinars

- Cuff Kit[™] Connection Monthly Technical Assistance and Peer Learning Series
 - Jan. 18, 2023 PowerPoint | Recording
 - Feb. 15, 2023 PowerPoint | Recording
 - March 15, 2023 PowerPoint
 - April 19, 2023 PowerPoint | Recording
 - May 17, 2023 PowerPoint | Recording
- Maternal Cardiovascular Disease PowerPoint | Recording (May 22, 2023)
- Utilization of Self-Monitored Blood Pressure Kits to Support Perinatal Hypertension Management — PowerPoint | Recording (April 24, 2023)
- The Cuff Kit[™] Project Logistics/Data Meeting PowerPoint | Recording (Dec. 1, 2022)
- The Cuff Kit[™] Project Informational Meeting **PowerPoint** | **Recording** (Sept. 13, 2022)

Resources

- MHA CK Data Collection Spreadsheet (Revised January 2023)
- FAQs (Revised February 2023)
- Self-Measured Blood Pressure CPT Coding



SMM Events by Complication Group

100% 90% 80% 70% 60% ٠ 50% 40% 30% 20% 10% 0% 2016 2017 2018 2019 2020 2021 2022 2023 Renal ■ Respiratory ■ Other Medical ■ Other OB ■ Anminotic Embolism ■ Sepsis ■ Hemorrhage ■ Cardiac

SMM Events by Complication Group as Percent of Total

2022 Represents

- 21% increase in overall SMM Incidence since 2016
- Driven by
 - 130% increase in Renal
 - 37% increase in Respiratory
 - 30% increase in Other Medical

Lessons Learned.....

- Started with low hanging fruit
- Realized quickly that we brought our own bias

Table 4: Question Assessing Visualization of Department of Health and Senior ServicesCampaign for Pregnancy-Associated Deaths due to Car Accidents

Question	Answer
	(n=1509)
Have you seen this poster	178 (11.8)
before?	
If yes, at what location?	
Online advertisement	57 (32.0)
Billboard	25 (14.0)
Health center or health	109 (61.2)
Department	
Doctor's office	101 (56.7)
Bus stop	23 (12.9)
Other	10 (5.6)

All data is presented in counts and percentages (%).



				1				
	What health problems do you	High blood pressure	1364 (78.5)					
Table 2	think can happen as a result of	Diabetes	1039 (59.8)	v in Missouri				
	being pregnant (check all that	Heart disease	525 (30.2)	ly in Missouri.				
	apply)?	Thyroid disease	514 (29.6)					
Questic		Depression or anxiety	1384 (79.6)	percentage)				
Are voi		Mental health	863 (49.7)	2)				
due te		problem such as		.2)				
due to		addiction						
Do you		Blood clots	1098 (63.2)	2)				
in Miss		Stroke or clot in brain	674 (38.8)	_ ^ _				
		Complications from	1058 (60.9)					
states?		surgery						
Do you		Infections	1127 (64.8)	7)				
as a re		Violence	588 (33.8)	_ ′ _				
45 4 10		Self-inflicted	631 (36.3)					
		None	72 (4.1)	_				
If ve	Which 2 conditions listed do you	Severe bleeding	989 (56.9)	_				
that	believe are most commonly	COVID-19 infection	68 (3.9)					
uiat	connected with a pregnancy-	Infections (other than	276 (15.9)					
preç	related death?	COVID)	750 (40.0)	_				
		Blood pressure	758 (43.6)					
		problems	07 (2.0)	_				
		Heart disease	67 (3.9)	- 1				
Do you		Blood clots	361 (20.8)	4)				
aroun t		Stroke	106 (6.1)	-				
group t		Complications from	359 (20.7)					
pregna			69 (2.0)	-				
-		Violonco	125 (7.9)	-				
		Solf inflicted	110 (6.3)	-				
		None of the above	70 (4.5)	-				
		(do not believe any of	13 (4.3)					
		these cause death)						
	1	(Incoe cause ucall)	1					



			Age					Rac	e					Region		
Question	18-24 (n=221)	25-34 (n=373)	35-44 (n=390)	45-54 (n=289)	55+ (n=235)	p- value	Black (n=260)	White (n=1353)	Am In/Pac Island (n=30)	Other (n=95)	p- value	1	2	3	4	p- value
Are you aware of maternal deaths?	193 (87.3)	289 (77.5)	278 (71.3)	219 (75.8)	174 (74.0)	< 0.001	208 (80.0)	1056 (78.0)	25 (83.3)	65 (73.9)	0.583	441 (79.5)	249 (74.6)	491 (80.4)	170 (75.2)	0.112
Do you think deaths are high?	129 (66.8)	162 (56.1)	158 (56.8)	101 (46.1)	90 (51.7)	< 0.001	126 (60.6)	608 (57.6)	16 (64.0)	38 (58.5)	0.801	251 (56.9)	132 (53.0)	314 (64.0)	89 (52.4)	0.006
Do you know someone?	50 (22.6)	58 (15.5)	46 (11.8)	28 (9.7)	22 (9.4)	< 0.001	47 (18.1)	187 (13.8)	9 (30.0)	12 (13.6)	0.038	78 (14.1)	37 (11.1)	96 (15.7)	43 (19.0)	0.056
Family member	17 (34.0)	12 (20.7)	16 (34.8)	4 (14.3)	5 (22.7)		11 (28.9)	40 (27.0)	1 (12.5)	2 (20.0)		10 (18.5)	15 (45.5)	22 (27.2)	7 (19.4)	
Friend	16 (32.0)	20 (34.5)	15 (32.6)	7 (25.0)	6 (27.3)		14 (36.8)	39 (26.4)	6 (75.0)	5 (50.0)		19 (35.2)	6 (18.2)	25 (30.9)	14 (38.9)	
Acquaintance	8 (16.0)	17 (29.3)	11 (23.9)	10 (35.7)	7 (31.8)	0 4 1 9	6 (15.8)	46 (31.1)	0 (0.0)	1 (10)	0 1 1 4	14 (25.9)	9 (27.3)	19 (23.5)	11 (30.6)	0.511
Public Figure	3 (6.0)	1 (1.7)	0 (0.0)	0 (0.0)	1 (4.5)	0.410	2 (5.3)	3 (2.0)	0 (0.0)	0 (0.0)	0.114	1 (1.9)	1 (3.0)	3 (3.7)	0 (0.0)	0.011
Other	4 (8.0)	7 (12.1)	2 (4.3)	6 (21.4)	3 (13.6)		4 (10.5)	17 (11.5)	0 (0.0)	1 (10)		8 (14.8)	2 (6.1)	9 (11.1)	3 (8.3)	
None of above	2 (4.0)	1 (1.7)	2 (4.3)	1 (3.6)	0 (0.0)		1 (2.6)	3 (2.0)	1 (12.5)	1 (10.0)		2 (3.7)	0 (0.0)	3 (3.7)	1 (2.8)	

			Age			Race							Region					
Were you concerned about dying during pregnancy?	18-24 (n=221)	25-34 (n=373)	35-44 (n=390)	45-54 (n=289)	55+ (n=235)	p- value	Black (n=260)	White (n=1353)	Am In/Pac Island (n=30)	Other (n=95)	p- value	1	2	3	4	p- value		
Not at all	57 (25.8)	104 (27.9)	131 (33.6)	127 (43.9)	146 (62.1)		94 (36.2)	516 (38.1)	10 (33.3)	32 (36.4)		219 (39.5)	119 (35.6)	223 (36.5)	89 (39.4)			
A little	58 (26.2)	115 (30.8)	117 (30.0)	80 (27.7)	38 (16.2)		65 (25.0)	379 (28.0)	11 (36.7)	20 (22.7)		143 (25.8)	98 (29.3)	173 (28.3)	60 (26.5)			
Somewhat	49 (22.2)	79 (21.2)	80 (20.5)	57 (19.7)	35 (14.9)	< 0.001	52 (20.0)	263 (19.4)	4 (13.3)	19 (21.6)	0.037	110 (19.8)	60 (18.0)	122 (20.0)	44 (19.5)	0.878		
Very	33 (14.9)	42 (11.3)	32 (8.2)	16 (5.5)	12 (5.1)		19 (7.3)	117 (8.6)	5 (16.7)	12 (13.6)		47 (8.5)	34 (10.2)	49 (8.0)	23 (10.2)			
Extremely	24 (10.9)	33 (8.8)	30 (7.7)	9 (3.1)	4 (1.7)		30 (11.5)	78 (5.8)	0 (0.0)	5 (5.7)		36 (6.5)	23 (6.9)	44 (7.2)	10 (4.4)			
What time period do you believe has the highest risk for death?																		
Early	25 (11 3)	36 (9.7)	50 (12.8)	48 (16.6)	37 (15 7)		31 (11.9)	155 (11.5)	5 (16 7)	12 (13.6)		55 (9.9)	41 (12 3)	74 (12 1)	32 (14-2)			
Mid	9 (4.1)	18 (4.8)	25 (6.4)	14 (4.8)	15 (6.4)		18 (6.9)	59 (4.4)	2 (6.7)	3 (3.4)	-	26 (4 7)	15 (4.5)	25 (4 1)	16 (7.1)			
Late	22 (10.0)	36 (9.7)	43 (11.0)	32 (11.1)	31 (13.2)	0.042	22 (8.5)	151 (11.2)	2 (6.7)	11 (12.5)	0.805	63 (11.4)	35 (10.5)	58 (9.5)	29 (12.8)	0.191		
During labor (before pushing)	21 (9.5)	44 (11.8)	43 (11.0)	34 (11.8)	17 (7.2)		26 (10.0)	134 (9.9)	3 (10.0)	7 (8.0)		61 (11.0)	22 (6.6)	60 (9.8)	26 (11.5)			
During deliverv	107 (48.4)	166 (44.5)	174 (44.6)	121 (41.9)	86 (36.6)		118 (45.4)	565 (41.8)	15 (50.0)	35 (39.8)		225 (40.5)	162 (48.5)	264 (43.2)	81 (35.8)			
(while pushing)																		
After delivery in the hospital	17 (7.7)	40 (10.7)	34 (8.7)	14 (4.8)	25 (10.6)		26 (10.0)	146 (10.8)	2 (6.7)	10 (11.4)		71 (12.8)	25 (7.5)	68 (11.1)	20 (8.8)			
After discharge from hospital	1 (0.5)	10 (2.7)	3 (0.8)	5 (1.7)	7 (3.0)		5 (1.9)	56 (4.1)	0 (0.0)	2 (2.3)		22 (4.0)	9 (2.7)	24 (3.9)	8 (3.5)			
After postpartum visit	2 (0.9)	4 (1.1)	5 (1.3)	5 (1.7)	0 (0.0)		1 (0.4)	24 (1.8)	0 (0.0)	2 (1.7)		10 (1.8)	7 (2.1)	7 (1.1)	2 (0.9)			
None of the above	17 (7.7)	19 (5.1)	13 (3.3)	16 (5.5)	17 (7.2)		13 (5.0)	63 (4.7)	1 (3.3)	6 (6.8)		22 (4.0)	18 (5.4)	31 (5.1)	12 (5.3)			



References:

• Grandi SM, Filion KB, Yoon S, et al. Cardiovascular Disease-Related Morbidity and Mortality in Women With a History of Pregnancy Complications: Systematic Review and Meta-Analysis. *Circulation*. 2019;139(8):1069-1079. doi:10.1161/CIRCULATIONAHA.118.036748

• Shalom G, Shoham-Vardi I, Sergienko R, Wiznitzer A, Sherf M, Sheiner E. Is preeclampsia a significant risk factor for long-term hospitalizations and morbidity? *J Matern Fetal Neonatal Med.* 2013;26(1):13-15. doi:10.3109/14767058.2012.718386

• Wu P, Haththotuwa R, Kwok CS, et al. Preeclampsia and Future Cardiovascular Health: A Systematic Review and Meta-Analysis. Circ: Cardiovascular Quality and Outcomes. 2017;10(2). doi:10.1161/CIRCOUTCOMES.116.003497

• Barnas J. Maternal Mortality and Health Disparities. MOST Policy Initiatives. Published January 18, 2021. Accessed April 23, 2023. https://mostpolicyinitiative.org/science-note/maternal-mortality-and-health-disparities/

• Missouri March of Dimes Peristats.; 2023:2. Accessed February 14, 2023. https://www.marchofdimes.org/Peristats/ViewSubtopic.aspx?reg=29&top=2&stop=10&lev=1&slev=4&obj=3

• Tucker KL, Bankhead C, Hodgkinson J, et al. How Do Home and Clinic Blood Pressure Readings Compare in Pregnancy?: A Systematic Review and Individual Patient Data Meta-Analysis. *Hypertension*. 2018;72(3):686-694. doi:10.1161/HYPERTENSIONAHA.118.10917

• Tucker KL, Mort S, Yu LM, et al. Effect of Self-monitoring of Blood Pressure on Diagnosis of Hypertension During Higher-Risk Pregnancy: The BUMP 1 Randomized Clinical Trial. JAMA. 2022;327(17):1656. doi:10.1001/jama.2022.4712

• Dagher RK, Linares DE. A Critical Review on the Complex Interplay between Social Determinants of Health and Maternal and Infant Mortality. Children. 2022;9(3):394. doi:10.3390/children9030394

• Perry H, Sheehan E, Thilaganathan B, Khalil A. Home blood-pressure monitoring in a hypertensive pregnant population: Home BP monitoring in pregnancy hypertension. *Ultrasound Obstet Gynecol.* 2018;51(4):524-530. doi:10.1002/uog.19023

• Kalafat E, Benlioglu C, Thilaganathan B, Khalil A. Home blood pressure monitoring in the antenatal and postpartum period: A systematic review meta-analysis. *Pregnancy Hypertension*. 2020;19:44-51. doi:10.1016/j.preghy.2019.12.001

• Khoong EC, Commodore-Mensah Y, Lyles CR, Fontil V. Use of Self-Measured Blood Pressure Monitoring to Improve Hypertension Equity. *Curr Hypertens Rep.* 2022;24(11):599-613. doi:10.1007/s11906-022-01218-0

• Bress AP, Cohen JB, Anstey DE, et al. Inequities in Hypertension Control in the United States Exposed and Exacerbated by COVID-19 and the Role of Home Blood Pressure and Virtual Health Care During and After the COVID-19 Pandemic. *JAHA*. 2021;10(11):e020997. doi:10.1161/JAHA.121.020997

• Hoppe KK, Thomas N, Zernick M, et al. Telehealth with remote blood pressure monitoring compared with standard care for postpartum hypertension. *American Journal of Obstetrics and Gynecology*. 2020;223(4):585-588. doi:10.1016/j.ajog.2020.05.027

• Li W, Kim CS, Howell EA, et al. Économic Evaluation of Prenatal and Postpartum Care in Women With Gestational Diabetes and Hypertensive Disorders of Pregnancy: A Systematic Review. Value Health. 2022;25(12):2062-2080. doi:10.1016/j.jval.2022.07.014

 Postel-Vinay N, Shao JD, Pinton A, Servais A, Gebara N, Amar L. Home Blood Pressure Measurement and Self-Interpretation of Blood Pressure Readings During Pregnancy: Hy-Result e-Health Prospective Study. VHRM. 2022;Volume 18:277-287. doi:10.2147/VHRM.S350478

Murphy MSQ, Smith GN. Pre-eclampsia and Cardiovascular Disease Risk Assessment in Women. Am J Perinatol. 2016;33(8):723-731. doi:10.1055/s-0036-1572536

• Honigberg MC, Zekavat SM, Aragam K, et al. Long-Term Cardiovascular Risk in Women With Hypertension During Pregnancy. Journal of the American College of Cardiology. 2019;74(22):2743-2754. doi:10.1016/j.jacc.2019.09.052

• Lane-Cordova A, Khan S, Grobman W, et al. Long-Term Cardiovascular Risks Associated With Adverse Pregnancy Outcomes. J Am Coll Cardiol. 2019 Apr, 73 (16) 2106-

2116.https://doi.org/10.1016/j.jacc.2018.12.092

• Missouri Pregnancy Associated Mortality Review 2017-2019 Annual Report. Missouri Department of Health and Senior Services. (June 2022)

• Loop MS, Howard G, De Los Campos G, et al. Heat Maps of Hypertension, Diabetes Mellitus, and Smoking in the Continental United States. Circ: Cardiovascular Quality and Outcomes.

2017;10(1):e003350. doi:10.1161/CIRCOUTCOMES.116.003350

• Examining the 12-month postpatum medicaid coverage option for Missouri. Published online February 2022. Accessed April 25, 2023. https://mffh.org/wp-content/uploads/2021/05/Postpartum-coverage.pdf